To identify molecules with the greatest chance of success, the transition of your molecule from candidate selection to Proof-of-Concept (POC) needs to be fast and cost-effective.
Quotient Sciences’ Translational Pharmaceutics® approach enables First-In-Human studies by transitioning your drug molecule into clinical development through to POC quickly through the integration of:
“R552 is a potent and selective RIP1 kinase inhibitor that blocks inflammatory cell death downstream of death receptors. It is being developed at Rigel Pharmaceuticals for treatment of autoimmune and inflammatory disorders. We were very delighted to have Quotient on board and worked with us on the formulation development as well as the First in Human study of R552. During the course of project development, we were very impressed by Quotient’s responsiveness in communication, efficiency/flexibility in project management and the extensive knowledge/experience in formulation development, early phase clinical trial conduct and safety monitoring. Quotient is one of the best development partners that we have ever worked with and would recommend for future collaborations without any reservation.”
Dr Lucy Yan, Executive Medical Director at Rigel Pharmaceuticals